We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Unveiling Cencora (COR) Q4 Outlook: Wall Street Estimates for Key Metrics
Read MoreHide Full Article
Wall Street analysts forecast that Cencora (COR - Free Report) will report quarterly earnings of $4.55 per share in its upcoming release, pointing to a year-over-year increase of 18.5%. It is anticipated that revenues will amount to $88.16 billion, exhibiting an increase of 5.3% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone a downward revision of 3.6% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Cencora metrics that are commonly tracked and forecasted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Revenue- Total U.S. Healthcare Solutions' of $78.26 billion. The estimate suggests a change of +3.3% year over year.
Based on the collective assessment of analysts, 'Revenue- Total International Healthcare Solutions' should arrive at $7.75 billion. The estimate indicates a change of -2.5% from the prior-year quarter.
Analysts forecast 'Operating income- International Healthcare Solutions' to reach $157.49 million. The estimate is in contrast to the year-ago figure of $150.66 million.
Analysts predict that the 'Operating income- U.S. Healthcare Solutions' will reach $992.82 million. Compared to the current estimate, the company reported $872.41 million in the same quarter of the previous year.
Over the past month, Cencora shares have recorded returns of +6.7% versus the Zacks S&P 500 composite's +0.7% change. Based on its Zacks Rank #4 (Sell), COR will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .
View the Zacks #1 Rank List
Image: Bigstock
Unveiling Cencora (COR) Q4 Outlook: Wall Street Estimates for Key Metrics
Wall Street analysts forecast that Cencora (COR - Free Report) will report quarterly earnings of $4.55 per share in its upcoming release, pointing to a year-over-year increase of 18.5%. It is anticipated that revenues will amount to $88.16 billion, exhibiting an increase of 5.3% compared to the year-ago quarter.
The consensus EPS estimate for the quarter has undergone a downward revision of 3.6% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically use consensus earnings and revenue estimates as indicators of quarterly business performance, exploring analysts' projections for specific key metrics can offer valuable insights.
In light of this perspective, let's dive into the average estimates of certain Cencora metrics that are commonly tracked and forecasted by Wall Street analysts.
The collective assessment of analysts points to an estimated 'Revenue- Total U.S. Healthcare Solutions' of $78.26 billion. The estimate suggests a change of +3.3% year over year.
Based on the collective assessment of analysts, 'Revenue- Total International Healthcare Solutions' should arrive at $7.75 billion. The estimate indicates a change of -2.5% from the prior-year quarter.
Analysts forecast 'Operating income- International Healthcare Solutions' to reach $157.49 million. The estimate is in contrast to the year-ago figure of $150.66 million.
Analysts predict that the 'Operating income- U.S. Healthcare Solutions' will reach $992.82 million. Compared to the current estimate, the company reported $872.41 million in the same quarter of the previous year.
View all Key Company Metrics for Cencora here>>>Over the past month, Cencora shares have recorded returns of +6.7% versus the Zacks S&P 500 composite's +0.7% change. Based on its Zacks Rank #4 (Sell), COR will likely underperform the overall market in the upcoming period. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> .